Mr. Damian Kettlewell reports

BLISSCO ENTERS BILLION-DOLLAR COMPLEMENTARY AND ALTERNATIVE MEDICINE MARKET, APPOINTS DR. BRYN HYNDMAN TO ADVISORY BOARD

Dr. Bryn Hyndman, former medical director of Qi Integrated Health, is joining Blissco Cannabis Corp.'s advisory board.

Dr. Hyndman is a board-certified medical doctor with the Canadian College of Family Physicians (CCFP) and is a naturopath.

"We are focused on building a strong ecosystem that includes partners such as Dr. Hyndman to enable us to establish the Blissco brand as a premium craft cannabis product in the medical market and recreational market when it is legal," said Damian Kettlewell, chief executive officer of Blissco Cannabis.

A report by Grand View Research estimates that the complementary and alternative medicine market is expected to generate $196.87-billion in revenue globally by 2025.

"There is a gap in modern medicine; doctors are trained in chronic disease management and acute emergencies. Science has, until now, relied on double-blind, placebo-controlled trials where single drugs are studied in isolation, but there are a wide range of medical compounds in cannabis and they work synergistically. You can't break down a plant and isolate these ingredients because you will lose its essence," said Dr. Hyndman.

Blissco's cannabis extraction lab with the first Midas MIDAS XII Co2 extraction system in Canada will ensure that Blissco safely extracts therapeutic cannabis terpenes along with the whole plant oils, offering a full spectrum of benefits to patients.

"We are excited to work with Dr. Hyndman to ensure that our patient care model and medical cannabis products are aligned. As well, Blissco is pursuing clinical trial research partners and Dr. Hyndman's experience with medical cannabis will assist us with the design and rollout of our first clinical trial," said Mr. Kettlewell.

About Blissco Cannabis Corp.

Blissco owns, through its wholly owned subsidiary Blissco Holdings Ltd., a licence to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR), which was originally granted on March 29, 2018.

We seek Safe Harbor.